TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8517903

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 105
Study: 3203713

Group type: EXPERIMENTAL
Intervention: Normal release methyldopa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained release methyldopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both formulations of methyldopa
Number of subjects: 10
Study: 30659416

Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise (2 days/week, 60 min/session) with independent home exercise (3 days/week, ≥ 20 min/session)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 19
Study: 28398836

Group type: EXPERIMENTAL
Intervention: Quantitative information module
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Nudge module
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Quantitative information module (high numeracy)
Number of subjects: 213
Study: 25872506

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by the ABVN
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by ABVN pairing tones
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at auricular acupoints innervated by non‐ABVN pairing tones
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Number of subjects: 120
Study: 23540553

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 96
Study: 21752985

Group type: EXPERIMENTAL
Intervention: Self-sampling kit
Number of subjects: 9709

Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 9709

Group type: EXPERIMENTAL
Intervention: Combination of reminder letter and self-sampling
Number of subjects: 9709

Group type: EXPERIMENTAL
Intervention: Self-obtained samples
Number of subjects: 9709
Study: 18384120

Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 71
Study: 21600104

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 µg/kg
Number of subjects: 80
Study: 16117882

Group type: COMPARATOR
Intervention: Artificial neural network model using serum protein fingerprinting
Number of subjects: 106
Study: 12105352

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea syndrome
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (subjects without obstructive sleep apnea syndrome)
Number of subjects: 23
Study: 10734431

Group type: EXPERIMENTAL
Intervention: Deslorelin 700 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deslorelin 2100 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (saline, 2 mL, i.m.)
Number of subjects: 24
Study: 7857353

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study: 2683564

Group type: EXPERIMENTAL
Intervention: Transfixation and/or repair of the triangular ligament after closed reduction of the fractured radius
Number of subjects: 41

Group type: COMPARATOR
Intervention: Closed manipulation and above-the-elbow plaster cast
Number of subjects: 41
Study: 989409

Group type: EXPERIMENTAL
Intervention: Sleep deprivation/chlorimipramine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorimipramine therapy
Number of subjects: 0
Study: 31118178

Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2104
Study: 28606206

Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (home visiting intervention plus standard care)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Standard Clinic Care (SC)
Number of subjects: 1238
Study: 26562569

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24552647

Group type: COMPARATOR
Intervention: Total polyphenol intake (Q5 vs. Q1)
Number of subjects: 7172

Group type: COMPARATOR
Intervention: Flavanols
Number of subjects: 7172

Group type: COMPARATOR
Intervention: Lignans
Number of subjects: 7172

Group type: COMPARATOR
Intervention: Hydroxybenzoic acids
Number of subjects: 7172
Study: 22093663

Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) training for 12 weeks, 3 times a week
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) training
Number of subjects: 51
Study: 19474409

Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 16740505

Group type: EXPERIMENTAL
Intervention: Sun Protection is Fun! (SPF) intervention
Number of subjects: 245
Study: 15308522

Group type: EXPERIMENTAL
Intervention: Vaccination schedule at 0, 1, and 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vaccination schedule at 0, 1, and 6 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study: 11224758

Group type: COMPARATOR
Intervention: SonoVue (0.003 to 0.12 mL/kg for healthy volunteers; 4 mL for COPD patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: SonoVue
Number of subjects: 78
Study: 9767284

Group type: EXPERIMENTAL
Intervention: Low incremental dose regimen
Number of subjects: 20

Group type: COMPARATOR
Intervention: High incremental dose regimen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 20
Study: 7977175

Group type: EXPERIMENTAL
Intervention: VAPE alternating with CCM
Number of subjects: 27

Group type: COMPARATOR
Intervention: CCM alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall survival for CR patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall survival for PR patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall survival for NR patients
Number of subjects: 27
Study: 2532583

Group type: EXPERIMENTAL
Intervention: Once-a-day sustained release preparation of anhydrous theophylline
Number of subjects: 10
Study: 5428778

Group type: EXPERIMENTAL
Intervention: Pulmonary scans showing high probability of pulmonary embolism (24 patients)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diffuse, patchy, and non‐segmental perfusion defects (28 patients)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Normal lung scans (12 patients)
Number of subjects: 71
Study: 30086103

Group type: EXPERIMENTAL
Intervention: 0.2% polyhexamethylene biguanide (PHMB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.8% metronidazole (control group)
Number of subjects: 24
Study: 28274722

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation combined with 20-min tcDCS for 5 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 26154250

Group type: EXPERIMENTAL
Intervention: Standard training plus simulation‐based mastery training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 52
Study: 24121307

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, guided, self‐help, problem‐solving intervention through the Internet (n=49)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waitlist control group (n=47)
Number of subjects: 96
Study: 21903983

Group type: EXPERIMENTAL
Intervention: Intensive angiotensin blockade
Number of subjects: 543
Study: 19012954

Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef vaccine (n=1494)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo (n=1506)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef vaccine
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 16333821

Group type: EXPERIMENTAL
Intervention: Health promotion intervention (details not specified)
Number of subjects: 75
Study: 11835021

Group type: EXPERIMENTAL
Intervention: Initial 2 shocks programmed at 2 energy steps above DFT++ (typically 4‐6 J, maximum 10 J) with subsequent shocks at maximum energy
Number of subjects: 702

Group type: COMPARATOR
Intervention: All shocks programmed at maximum energy
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Subgroup randomization to energy levels of 0, 1, 2, 3, or 4 steps above implant DFT++ for conversion testing
Number of subjects: 702
Study: 10522991

Group type: EXPERIMENTAL
Intervention: 17‐beta estradiol/norethisterone for 6 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 8547869

Group type: EXPERIMENTAL
Intervention: Cobe Spectra
Number of subjects: 10

Group type: COMPARATOR
Intervention: Haemonetics MCS‐3P
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of both machines
Number of subjects: 10
Study: 2328298

Group type: EXPERIMENTAL
Intervention: 200 mg N-acetylcysteine (NAC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg N-acetylcysteine (NAC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg N-acetylcysteine (NAC) twice a day for 5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1200 mg N-acetylcysteine (NAC)
Number of subjects: 10
Study: 7459147

Group type: EXPERIMENTAL
Intervention: Canadian Air Force exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal activities (Control)
Number of subjects: 0
Study: 29547610

Group type: EXPERIMENTAL
Intervention: Lavender oil aromatherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tea tree oil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group with no oil
Number of subjects: 70
Study: 29027274

Group type: EXPERIMENTAL
Intervention: Natural turmeric matrix formulation (CNTMF), 500 mg dose
Number of subjects: 45

Group type: COMPARATOR
Intervention: Curcumin with volatile oil formulation, 500 mg dose
Number of subjects: 45

Group type: COMPARATOR
Intervention: Curcumin with phospholipids formulation, 500 mg dose
Number of subjects: 45
Study: 25632021

Group type: EXPERIMENTAL
Intervention: Controlled breathing (timed respiratory frequency with metronome, target tidal volumes displayed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled breathing
Number of subjects: 12
Study: 24008923

Group type: EXPERIMENTAL
Intervention: Glucose (GL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: White Rice (WR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rolled Barley (BAR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 7
Study: 21087706

Group type: EXPERIMENTAL
Intervention: Individualized management with Hemostasis Management System Plus (HMS) following a modified protocol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Weight‐based anticoagulation management using activated clotting time (ACT)
Number of subjects: 90
Study: 19005406

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 16997676

Group type: EXPERIMENTAL
Intervention: Tobacco screening
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Smoking-related discussions
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Advice to quit smoking
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Assessment of readiness to quit
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Referral for smoking cessation
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Physician empathy/encouragement
Number of subjects: 871
Study: 14617313

Group type: EXPERIMENTAL
Intervention: Unmodified pooled random‐donor PLT concentrates
Number of subjects: 598

Group type: COMPARATOR
Intervention: UV‐B‐irradiated PCs
Number of subjects: 598

Group type: COMPARATOR
Intervention: Filtered PCs
Number of subjects: 598

Group type: COMPARATOR
Intervention: Filtered random‐donor apheresis PLTs
Number of subjects: 598
Study: 11094667

Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl 5 micrograms/ml in bupivacaine 0.2% with adrenaline 5 micrograms/ml at a rate of 2 ml/h for more than 48 hours
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural infusion of fentanyl 5 micrograms/ml in bupivacaine 0.2% without adrenaline at a rate of 2 ml/h for more than 48 hours
Number of subjects: 90
Study: 9368200

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NIMH LCM-p
Number of subjects: 30
Study: 8218756

Group type: EXPERIMENTAL
Intervention: 20 mg ranitidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40 mg ranitidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60 mg ranitidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 80 mg ranitidine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3304515

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha 10 mg intravesically
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29873315

Group type: EXPERIMENTAL
Intervention: Smartphone-based Heart Health Application
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1000
Study: 27009868

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 1887

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1887
Study: 23970480

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 12
Study: 23652617

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 66
Study: 20110146

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (rosiglitazone and pioglitazone)
Number of subjects: 2860
Study: 18180410

Group type: EXPERIMENTAL
Intervention: Group A (advised to reduce fat and to increase complex carbohydrate intake)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Group B (advised to reduce both fat and sugar and to increase complex carbohydrate intake)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Control group (given no advice)
Number of subjects: 1013
Study: 15699229

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.5 g/d)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 12553508

Group type: EXPERIMENTAL
Intervention: Two drains inserted (one below the fascia and one subcutaneously)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No drains
Number of subjects: 22
Study: 9728902

Group type: EXPERIMENTAL
Intervention: Befloxatone (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amitriptyline (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7857357

Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg/day) for 60 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 101
Study: 2658674

Group type: EXPERIMENTAL
Intervention: Propofol (maintenance dose controlled to maintain light sleep levels C0 to D1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol (maintenance dose controlled to maintain deep sleep levels)
Number of subjects: 20
Study: 1060201

Group type: EXPERIMENTAL
Intervention: Elmex fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 6102487

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg twice daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketotifen (both dosages)
Number of subjects: 50
Study: 30828846

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28991599

Group type: EXPERIMENTAL
Intervention: Community-based education and coaching intervention (3-month group education + 3-month coaching)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study: 25785968

Group type: EXPERIMENTAL
Intervention: 40 mg mongersen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 160 mg mongersen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg mongersen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24251826

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 21724462

Group type: EXPERIMENTAL
Intervention: Bortezomib plus rituximab
Number of subjects: 676

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 676
Study: 19588654

Group type: EXPERIMENTAL
Intervention: Cold cabbage leaves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate hot and cold compresses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17542203

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching agent (Opalescence, OPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo agent (PLA)
Number of subjects: 40
Study: 15366527

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution (Periogard) mouth rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride solution (Cepacol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution (Periogard)
Number of subjects: 60
Study: 12079502

Group type: EXPERIMENTAL
Intervention: House dust mite barrier bedding
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo bedding
Number of subjects: 47
Study: 9833852

Group type: EXPERIMENTAL
Intervention: HAART (zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, ritonavir 600 mg twice daily)
Number of subjects: 15
Study: 7862842

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flumazenil + Midazolam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 10
Study: 2476608

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study: 241192

Group type: EXPERIMENTAL
Intervention: Benzquinamide (0.7 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30981791

Group type: EXPERIMENTAL
Intervention: Underwater EMR (UEMR)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional EMR (CEMR)
Number of subjects: 210
Study: 29074303

Group type: COMPARATOR
Intervention: 0.9% saline (P)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: dexmedetomidine (1 μg kg−1, PLD)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: dexmedetomidine (2 μg kg−1, PHD)
Number of subjects: 6
Study: 26446165

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous bolus of methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23377389

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 22133340

Group type: EXPERIMENTAL
Intervention: Directional speech alert messages
Number of subjects: 38

Group type: COMPARATOR
Intervention: High rate of false alarms
Number of subjects: 38
Study: 19010447

Group type: EXPERIMENTAL
Intervention: Telephone-based self-management program (5 sessions with a nurse trained in MI counseling)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (received courtesy calls)
Number of subjects: 22
Study: 17274922

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2.5 years followed by aromatase inhibitor for 2.5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 years of aromatase inhibitor
Number of subjects: 0
Study: 15265851

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menaquinone) 45 mg/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (symptomatic therapy for ascites and dietary advice)
Number of subjects: 40
Study: 12403915

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCTs from Japan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case-control/cohort studies from Japan
Number of subjects: 0
Study: 9615868

Group type: EXPERIMENTAL
Intervention: VOL
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 8127562

Group type: EXPERIMENTAL
Intervention: Radial keratotomy surgery
Number of subjects: 328
Study: 2631000

Group type: EXPERIMENTAL
Intervention: Igel 67 (Prima)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bausch & Lomb 70
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Closed eye wear
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open eye wear
Number of subjects: 10
Study: 791586

Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone daily for 2 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 750 mg naproxen daily for 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 15
Study: 30847805

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat administration of triamcinolone acetonide ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone acetonide crystalline suspension (CS)
Number of subjects: 0
Study: 27807771

Group type: EXPERIMENTAL
Intervention: 2-week restriction
Number of subjects: 108

Group type: COMPARATOR
Intervention: 6-week restriction
Number of subjects: 108
Study: 26206737

Group type: EXPERIMENTAL
Intervention: SafeR pacing algorithm
Number of subjects: 373

Group type: COMPARATOR
Intervention: DDD pacing with a long atrioventricular delay (250 ms)
Number of subjects: 373